Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404371 | 1.00 | FAAH (0.64) | FAAHLMNALPAR1LPAR3L3MBTL1 | |
| SCHEMBL29666406 | 0.85 | HCAR2 (0.52) | FAAHLMNAL3MBTL1TDP1 | |
| SCHEMBL9608827 | 0.78 | GPR52 (0.47) | FAAHL3MBTL1TDP1TBXAS1PTAFR | |
| (2E)-Hexenoic Acid SCHEMBL1404373 | 0.78 | FAAH (0.52) | FAAHLMNATDP1TBXAS1CYP17A1 | |
| SCHEMBL29196901 | 0.76 | HCAR2 (0.56) | FAAHLMNAL3MBTL1TDP1 | |
| SCHEMBL14871736 | 0.76 | HCAR2 (0.56) | FAAHLMNAL3MBTL1TDP1 | |
| SCHEMBL1404389 | 0.76 | FAAH (0.53) | FAAHL3MBTL1TDP1TBXAS1TRPV1 | |
| SCHEMBL1404390 | 0.76 | FAAH (0.53) | FAAHL3MBTL1TDP1TBXAS1TRPV1 | |
| SCHEMBL23903382 | 0.74 | FAAH (0.59) | FAAHLMNAL3MBTL1TDP1TBXAS1 | |
| SCHEMBL10503253 | 0.74 | FAAH (0.59) | FAAHLMNAL3MBTL1TDP1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227479-B2 | DHA esters and use thereof in treatment and prevention of cardiovascular disease | PIERRE FABRE MEDICAMENT (FR) | 2012-07-24 | — | — | US | claimed |
| US-8034377-B2 | DHA esters and use thereof in treatment and prevention of cardiovascular disease | PIERRE FABRE MEDICAMENT (FR) | 2011-10-11 | — | — | US | claimed |
| US-20110237613-A1 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | BRUNE FREDERIQUE | 2011-09-29 | — | — | US | claimed |
| EP-2034999-B9 | DHA ESTERS AND USE THEREOF IN THE TREATMENT AND THE PREVENTION OF CARDIOVASCULAR DISEASES | PF MEDICAMENT (FR) | 2011-03-09 | — | — | EP | claimed |
| EP-2034999-B1 | DHA ESTERS AND USE THEREOF IN THE TREATMENT AND THE PREVENTION OF CARDIOVASCULAR DISEASES | PF MEDICAMENT (FR) | 2010-11-24 | — | — | EP | claimed |
| US-20090312354-A1 | DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease | PIERRE FABRE MEDICAMENT (FR) | 2009-12-17 | — | — | US | claimed |
| EP-2034999-A2 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | Pierre Fabre Médicament S.A. (FR) | 2009-03-18 | — | — | EP | claimed |
| WO-2007147899-A2 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | claimed |
| US-20150291507-A1 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | PIERRE FABRE MEDICAMENT (FR) | 2015-10-15 | — | — | US | disclosed |
| EP-2603486-B1 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | PF MEDICAMENT (FR) | 2014-12-17 | — | — | EP | disclosed |
| EP-2603486-A1 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | Pierre Fabre Medicament (FR) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137768-A1 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | PIERRE FABRE MEDICAMENT (FR) | 2013-05-30 | — | — | US | disclosed |
| US-8227479-B2 | DHA esters and use thereof in treatment and prevention of cardiovascular disease | PIERRE FABRE MEDICAMENT (FR) | 2012-07-24 | — | — | US | disclosed |
| WO-2012020094-A1 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | PIERRE FABRE MEDICAMENT (FR) | 2012-02-16 | — | — | WO | disclosed |
| US-20110237613-A1 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | BRUNE FREDERIQUE | 2011-09-29 | — | — | US | disclosed |
| EP-2034999-B9 | DHA ESTERS AND USE THEREOF IN THE TREATMENT AND THE PREVENTION OF CARDIOVASCULAR DISEASES | PF MEDICAMENT (FR) | 2011-03-09 | — | — | EP | disclosed |
| EP-2034999-B1 | DHA ESTERS AND USE THEREOF IN THE TREATMENT AND THE PREVENTION OF CARDIOVASCULAR DISEASES | PF MEDICAMENT (FR) | 2010-11-24 | — | — | EP | disclosed |
| US-20090312354-A1 | DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease | PIERRE FABRE MEDICAMENT (FR) | 2009-12-17 | — | — | US | disclosed |
| EP-2034999-A2 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | Pierre Fabre Médicament S.A. (FR) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007147899-A2 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312354-A1 | DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease | ADH1B, ADH4, ADH7 | FAAH 514/4885LMNA 463/4885LPAR1 921/4885 |
| US-20110237613-A1 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | ADH1B, ADH4, ADH7 | FAAH 514/4885LMNA 463/4885LPAR1 921/4885 |
| US-20130137768-A1 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | VKORC1L1, VKORC1, GGPS1 | FAAH 287/4885LMNA 241/4885LPAR1 592/4885 |
| US-20150291507-A1 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES | VKORC1L1, VKORC1, ALOX5 | FAAH 205/4885LMNA 225/4885LPAR1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.